Eight in 10 adults agree that adult smokers should have access to smoke-free options, while 76% worry that decisions are based on ideology rather than science and facts STAMFORD, Conn.–(BUSINESS WIRE)–A new international survey conducted by Povaddo and commissioned by Philip Morris International Inc. (NYSE: PM) reveals strong global support for smoke-free alternatives to cigarettes … [Read more…]

– Partner Curasense will market Equazen® products featuring a clinically researched combination of essential fatty acids across pharmacies, healthcare stores and online pharmacies. LUGANO, Switzerland–(BUSINESS WIRE)–#GLAsupplements–SFI Health™ EMEA, the regional entity of SFI Health™, a global leader in natural healthcare, and Curasense BV (Curasense), a Belgian company specializing in the distribution and development of high-quality … [Read more…]

FRAMINGHAM, Mass. & SALISBURY, England–(BUSINESS WIRE)–KalVista Pharmaceuticals, Inc. (“KalVista”) (NASDAQ: KALV), announced today the pricing of its offering of $125.0 million aggregate principal amount of 3.250% Convertible Senior Notes due 2031 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of … [Read more…]

Advanced bioprocessing solutions from Thermo Fisher to support large-scale production and global access to cell and gene therapies WALTHAM, Mass.–(BUSINESS WIRE)–Thermo Fisher Scientific Inc., the world leader in serving science, today announced that Dr. Park, an emerging viral vector contract development and manufacturing organization (CDMO) based in South Korea, has selected Thermo Fisher to provide … [Read more…]

ATLANTA–(BUSINESS WIRE)–Mirion Technologies, Inc. (“Mirion”) (NYSE: MIR) today announced the commencement of an underwritten public offering of $350.0 million of shares of Mirion’s Class A common stock (the “common stock offering”). Mirion also intends to grant the underwriters a 30-day option to purchase up to an additional $50.0 million of shares of its Class A … [Read more…]

FRAMINGHAM, Mass. & SALISBURY, England–(BUSINESS WIRE)–KalVista Pharmaceuticals, Inc. (“KalVista”) (NASDAQ: KALV) announced today that it intends to offer, subject to market conditions and other factors, $110.0 million aggregate principal amount of Convertible Senior Notes due 2031 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A … [Read more…]

Comprehensive testing service fast tracks answers and accelerates care pathways for children DENVER–(BUSINESS WIRE)–FronteraCare, a subsidiary of Frontera and a pioneer in advancing health equity, today announced the launch of its Diagnostics Network, a first-of-its-kind service that helps families bypass long waitlists and quickly understand their child’s needs. In a time when waitlists for assessment … [Read more…]

Companies partner with specialized providers to deploy GenAI, agentic AI for improved research, patient care, ISG Provider Lens® report says STAMFORD, Conn.–(BUSINESS WIRE)–$III #AgenticAI–Healthcare and life sciences enterprises are using generative AI (GenAI), agentic AI and analytics to transform patient care and drug development, according to a new research report published today by Information Services … [Read more…]

Clinically validated SmartHealth AI Stations anchor expansion into Clinical-Trial Optimization and Consumer Digital Health, creating multiple recurring-revenue opportunities TORONTO–(BUSINESS WIRE)–Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA: 3QP0) (“Predictmedix” or the “Company”), an emerging leader in AI-powered health and safety technology, today outlined a strategic plan to evolve from a single-product health-screening company into a … [Read more…]

– Ocrevus subcutaneous maintains consistent benefit-risk profile after two years – – New late-breaking data confirms Ocrevus significantly reduces disability progression in adults with advanced PPMS – – One-year data reinforce that majority of infants potentially exposed to Ocrevus during pregnancy or breastfeeding exhibit antibody responses – – Fenebrutinib two-year Phase II data demonstrate near-complete … [Read more…]